EVA Pharma Launches the First Egyptian Generic for Type 2 Diabetes Treatment Diaflozimet® Tablets

Cairo, October 12, 2020 – EVA Pharma announced the launch of Diaflozimet® tablets after having received approval from the Egyptian Drug Authority (EDA). Diaflozimet® is the first Egyptian generic that contains (dapagliflozin and metformin hydrochloride extended-release), which is indicated for the treatment of adults with type 2 diabetes. The drug combines two anti-hyperglycemic agents with complementary mechanisms of action, dapagliflozin, an inhibitor of sodium-glucose cotransporter 2 (SGLT2), and metformin hydrochloride (HCl) extended-release, a biguanide, is a once-daily oral tablet. According to clinical studies, the combination is proven effective in rapidly controlling blood glucose levels with a 3% reduction of HbA1C, up to 3.3Kg weight reduction, blood pressure reduction and protecting the kidney, heart, blood vessels and liver against diabetes complications.


This is a very promising treatment from many aspects” said Dr. Abbas Oraby, professor of endocrinology and member of the National Committee for Endocrinology and Diabetes of the Ministry of Health and Population. “SGLT2 inhibitors release glucose from the body via the kidneys; in addition to recent studies proving its effectiveness in improving heart and kidney functions which is vital for diabetic patients since 50% of renal dialysis patients are diabetic. While metformin improves cardiac functions by 15% in addition to its abilities to lower blood glucose levels and to inhibit liver cirrhosis and the deterioration of insulin-producing beta cells in the pancreas. Thus the combination of both active ingredients supports a more personalized approach to disease management, as it reduces the number of pills the diabetic patients need to take leading to better compliance. Also, as EVA Pharma is producing Diaflozimet® in four concentrations, the physician has the choice of more personalized doses to his patients.”

Download as PDF

EVA Pharma starts export of COVID-19 Antiviral Avipiravir® Worldwide

Cairo, September 17, 2020, EVA Pharma, one of the major international pharmaceutical companies headquartered in Cairo, started the process of export of the first shipment of Avipiravir® (favipiravir). Thus becoming the first In the Region and continent to manufacture generic favipiravir of the Japanese antiviral Avigan, which is used to treat severe influenza, respiratory viruses, and mild to moderate COVID-19 patients. The announcement comes a few months following EVA Pharma’s success in producing and delivering another COVID-19 treatment, Remdesivir-EVA Pharma®, to various countries on four continents. The Egyptian drug manufacturer adds it to its antiviral portfolio and acquires all approvals to commercialize it in its home market

“We are very happy to launch Avipiravir® in Egypt and other markets across the world as we approach the winter season with expected influenza cases. This is a medicine that was made for influenza and has shown positive results for COVID patients in countries around the world and is available at a very accessible price” said Dr. Riad Armanious, EVA Pharma Chief Executive Officer

“Avipiravir® is an oral antiviral drug, selectively inhibits viral replication inside the human cells and was initially authorized in Japan in 2014 as a flu treatment and it is now approved for emergency use by the Russian Ministry of Health as a potential treatment of COVID-19,” said Dr. Ashraf Hatem, former Minister of Health and Population and member of the High Committee for Respiratory Viruses at the Ministry of Higher Education and Scientific Research.

The hope continues as Dr. Adel Khattab, professor of chest diseases at Ain Shams University and member of the High Committee for Respiratory Viruses at the Ministry of Higher Education and Scientific Research explains: “During the COVID-19 pandemic, the Japanese health authorities provided the product in more than 40 countries to include in global clinical trials. Favipiravir yielded positive outcomes, alleviating fever after 3 days of treatment with a significantly rapid reduction of viral load at 4 days of treatment, encouraging many countries to add favipiravir to their COVID-19 treatment protocol as is the case for China and India”

With the continuous positive findings of Avipiravir® and EVA Pharma’s accredited facilities, by the European Union and other global health accreditations, the company has the ability to meet all demands of Avipiravir® in global markets


About EVA Pharma

EVA Pharma, one of the major multinational pharmaceutical companies headquartering in Cairo, Egypt while operating in more than 40 countries and one of the fastest-growing pharmaceutical companies in the MENA region. The company has partnerships with some of the leading international pharmaceutical names the world over and has a presence in 41 countries throughout the region. With a 3,000-strong team of some of the region’s most competent pharmaceutical professionals, Eva Pharma produces an average of 350,000 packs of more than 165 different drugs daily. Its state-of-the-art facilities are equipped with cutting-edge technology and are internationally recognized for innovation and the highest international quality standards.

download as pdf 

FDA Broadens Emergency Use Authorization for Remdesivir to Include All Hospitalized Patients for Treatment of COVID-19

  • The authorization will include mild and moderate, adult, and pediatric patients after being inclusive of severe cases.
  • According to recent studies, the drug reduces the mortality rate to less than 2%, accelerates recovery, and shortens hospitalization time.
  • Dr. Hossam Hossny: “The results of using Remdesivir in Egypt match the global results; I expect the World Health Organization to broaden the sphere of Remdesivir use furthermore.”


Cairo, September 1, 2020 – “EVA Pharma’s Remdesivir achieves positive global results and we are equipped to cooperate with many authorities to provide all needed quantities in Egypt and more than 100 countries” Dr. Riad Armanious, CEO.

Remdesivir granted broader authorization by the American Food and Drug Administration upon recent clinical studies which show its effect on accelerating COVID-19 patients’ recovery, not only in severe cases but also in mild and moderate conditions. Now the emergency use authorization includes use for adults and pediatrics alike regardless of the severity of their symptoms.

The initial issuance of the (EUA) of Remdesivir by the FDA, which was also adopted by other countries with access to the drug, was limited to patients with severe disease, which was defined as patients with low oxygen levels or need oxygen therapy or more intensive breathing support as a mechanical ventilator.

In its recent report, the FDA stated that the known potential benefits of Remdesivir outweigh its risks. Thus, the broader use authorization of the antiviral is based on a clinical trial conducted by the U.S. National Institute of Allergy and Infectious Diseases investigating 1062 hospitalized COVID-19 patients. The study showed the median time to recovery was 10 days for the Remdesivir group compared to 15 days for the placebo group. Other clinical trials have revealed a reduced mortality rate to less than 2% when patients are treated with Remdesivir.

It is important to note that the new authorization restricts the use of Remdesivir under medical supervision and only for hospitalized patients.

“The results of Remdesivir use in Egypt match the global results” confirmed Dr. Hossam Hossny, head of the Anti-Coronavirus Scientific Committee at the Ministry of Health and Population in a scientific conference attended by Minister of Health Dr. Hala Zayed, and presidential advisor for health affairs, Dr. Mohamed Awad Tag El-Den. Hosny anticipated that WHO broadens the indication of Remdesivir use in the future based on its benefits to mild and moderate conditions.

Egypt is one of the first countries to benefit from the use of Remdesivir after the licensing agreement between Gilead Sciences and EVA Pharma, allowing the company to be one of the first 3 facilities to manufacture the drug worldwide.

Following the FDA report and clinical studies, Dr. Riad Armanious, EVA Pharma CEO, emphasized his company’s keenness to provide Egypt and more than 100 countries with their needs of Remdesivir-EVA Pharma®.

In his statement, Armanious said the global results of using Remdesivir-EVA Pharma® corresponds to the positive results of the aforementioned clinical studies. Affirming the drug’s effect in accelerating recovery time and reducing the need for mechanical ventilation and hospital care.

EVA Pharma’s CEO shared his company’s pride to be one of the first three facilities in the world to have worked on Remdesivir manufacturing, covering the Egyptian need of the drug to treat severe cases as well as the needs of a number of countries around the globe.

Armanious assured that EVA Pharma is equipped to cooperate with all the Egyptian governmental health authorities to provide all needed quantities of COVID-19 treatments and other medicines.

About Remdesivir®:

A new Antiviral drug developed by Gilead Company and produced by EVA Pharma in Egypt. Remdesivir got an FDA license for exceptional use (Emergency Use Authorization) for treating new COVID-19 patients in hospitals in the United States and the United Kingdom & now it got the FDA Broadens Emergency Use Authorization including mild and moderate, adult and pediatric COVID-19 patients. It has also been approved by the European Medicines Agency “EMA” for use in severe and critical COVID-19 cases and it’s already used in many European countries. It also obtained full approval for official use in Japan for critical cases.


download as pdf

Two Egyptian-Manufactured Medicines are Soon Entering Europe and Canada


Cairo, 27 August 2020 — EVA Pharma announces a license agreement with a global pharmaceutical company to co-manufacturer large quantities of two medicines,  one is an anticoagulant that is used with COVID-19 patients, and the other treats benign prostatic hyperplasia (BPH). The drugs will soon be available in European countries and in Canada.

The news comes after the conclusion of all registration procedures with the relevant authorities at the European Union and Canada, with ensuring the drugs are produced, in EVA Pharma’s manufacturing facilities in Egypt, under the best global pharmaceutical standards of quality.

The managing director of Elbe life sciences, which is located in Hamburg, Germany, and owned by EVA Pharma, Dr. Nicolas Boge, spoke on the company’s continuous abidance by the top global quality standards in pharmaceutical manufacturing for locally distributed products as well as exported products. He pointed to the company’s plan to expand its production of medicines to European countries and other places around the world in addition to making available new medicines first to be introduced to the Egyptian market.

Boge revealed: “the first drug, which will soon be available in the Canadian market, is apixaban, an anticoagulant that is used to prevent blood clotting. The medicine is used with some cardiovascular diseases and recently has been used to prevent coagulation with some COVID-19 patients. While the second drug is solifenacin, treatment of benign prostatic hyperplasia (BPH), and soon will be available in European countries.

The anticoagulant Apixatrack® and BPH treatment Solitract®, like many other EVA Pharma products, already available in the Egyptian market and have gained the trust of many physicians and patients alike.

download as pdf

EVA Pharma Talent Academy Equips 3 Thousands Pharmacy Students for the Job Market

Cairo, August 19, 2020 – EVA Pharma launched its “EVA Pharma Talent Academy” to train around 3 thousand students of the final years at pharmacy schools from universities around the nation. This step highlights the interest of actively participating in qualifying students to the job market and mining for the talented and outstanding students in order to offer them job opportunities.

In the 10th year of the annual summer internship organized by EVA Pharma under the name “Career Exploration”, Dr. George Saadan, Head of Human Resources department at EVA Pharma, mentioned that the training program has started in mid-July virtually due to the current coronavirus pandemic. Later on, according to a survey among the interns, around 1700 students were scheduled to field visits to the factories and field practice.

Such field training were held parallel to the theoretical lectures, at which activities the company was keen on providing protective equipment to the students.

Saadan added, “The training course takes 7 weeks featuring 28 lectures by an elite group of expert professors in different fields.” The lecturers were professors from the American University in Cairo, ESLSCA French university branch in Cairo, the Egyptian-Japanese University for science and technology, in addition to company leaders alongside practical hands-on field training.

EVA Pharma schedules the celebration of the summer internship completion at the end of August. The event will include presenting certificates to all interns with special rewards to the outstanding interns of the group.

Saadan clarified that the students are taught about the fundamentals which a pharmacist needs to know in his career. The training sharpens many skills, personal and professional, and covers many aspects like sales, marketing, decision-making, management, quality, and pharmaceutical manufacturing.

“During various pharmacy visits, the interns also participated in patients’ awareness on diseases and medications, including vitamins and its correlation to immunity support, common-cold, and flu medications, and other dietary supplements”, Saadan added.

Highlighting that the door constantly remains open for interns to come with their innovative ideas, Saadan pointed that the ones who come up with the most outstanding ideas receive job offers at the company as soon as they graduate; in addition to the opportunity, the company is offering to all interns, to gain career-related experiences which help them plan their future career pathway and make their decisions.


download as pdf

EVA Pharma Releases 500 Thousand Packs of the Analgesic and Antipyretic Drug Paracetamol under the Trade Name Stopadol®


Cairo, August 10, 2020 – EVA Pharma intends to reinforce the available quantities of Paracetamol supply in the Egyptian market by releasing 500 thousand packs of Stopadol®, as a part of its mission to offer affordable & high-quality medications.


Dr. Ibram Wagih, marketing manager, says there is an increased demand for the medicines containing the active constituent Paracetamol due to its efficacy in reducing fever and alleviating pain in many cases. Aside from its high efficacy in reducing the fever of common cold and flu patients, the drug was also recently found to have this effect with COVID-19 patients, further increasing the demand for it.

Wagih added, “EVA Pharma is keen on offering the Egyptian market a number of medicines used in the treatment of the novel COVID-19, such as immunity boosters and vitamins, as Ossofortin®, Limitless C zinc®, and Milga®, the antiviral Remdesivir-EVA Pharma®, the anticoagulant Apixatrack® and the antibiotic treatment Moxiflox® in addition to Stopadol®”


Wagih highlighted the use of Stopadol® in symptoms relief in coronavirus, common cold, and fever, as well as alleviating mild to moderate pain in cases of headache, migraine, neuropathy, toothaches, strep throat, menstrual symptoms, sprain, rheumatoid arthritis, sciatica, backaches (lumbago), fibrosis, myopathy, joint stiffness, and edema.

About EVA Pharma

EVA Pharma, one of the major multinational pharmaceutical companies headquartering in Cairo, Egypt while operating in more than 40 countries and one of the fastest-growing pharmaceutical companies in the MENA region. The company has partnerships with some of the leading international pharmaceutical names the world over and has a presence in 41 countries throughout the region. With a 3,000-strong team of some of the region’s most competent pharmaceutical professionals, Eva Pharma produces an average of 350,000 packs of more than 165 different drugs daily. Its state-of-the-art facilities are equipped with cutting-edge technology and are internationally recognized for innovation and the highest international quality standards.

Download as PDF  

The Supreme Committee for Viruses Recognizes EVA Pharma as a Partner in the Eradication of Virus C in Egypt

Egyptian Study Proves Virus C Medicines Effective Against COVID-19

July 29, 2020, In light of World Hepatitis Day, celebrated on July 28th, the National Committee for Control of Viral Hepatitis, in collaboration with EVA Pharma, held a scientific conference on the updates of the fight against viral hepatitis.

During the conference, Dr. Gamal Esmat, vice chairman of the National Committee for Control of Viral Hepatitis of the Ministry of Health and Population, and the World Health Organization advisor, shared WHO’s goal to eliminate viral hepatitis globally by the year 2030. The goal which Egypt has already accomplished in virus C, Esmat highlighted “we are the first country to reach this rate of virus C elimination”.

Esmat commended EVA Pharma’s collaboration with Gilead Sciences to provide Egypt with a complete virus C treatment system, including high-quality medicines for relapsed cases and children.

As for the fight against hepatitis B, Esmat praised the novel medicine which EVA Pharma is planning its release soon. The medicine, as Esmat clarified, will benefit hepatitis B patients with renal dysfunction, unlike current treatments that have more load and kidney-related side effects.

On the margin of the conference, Esmat shared the positive results of an Egyptian study on the effect of HCV treatments on the novel coronavirus. The study, which was held at the faculty of sciences, Cairo University, has theoretically proved that HCV treatments as Nucleobuvir®, with active ingredient sofosbuvir, and Daclaviridin®, with active ingredient daclatasvir, accelerate the healing process, reduce the health effects and death rate of COVID-19.

Esmat added, after the conclusion of the study at Cairo’s faculty of sciences, 4 countries are now investigating the effects of HCV treatments on COVID-19. The countries are Egypt, Brazil, South Africa, and Iran.

Meanwhile, Dr. Riad Armanious, chief executive officer of EVA Pharma, said his company is keen on providing novel treatments to Egyptians; which allows the company to actively support the country’s quest to eliminate hepatitis C, in addition to its efforts to supply other antiviral treatments for hepatitis B, HIV, influenza, or coronavirus.

EVA Pharma owns the biggest pharmaceutical research center in the Middle East and Africa, Mounir Armanious Research Center (MARC), Armanious added. The company focuses on supporting scientific research and Egyptian researchers as well as the local manufacturing of active pharmaceutical ingredients and novel medicines.

While Dr. Amgad Talaat, general manager at EVA Pharma, said the company was a partner at the success of the president’s health campaign to eliminate hepatitis C. Talaat added, EVA Pharma, in collaboration with the Supreme Committee for Control of Viral Hepatitis and the Egyptian Society of Internal Medicine, will train more than a thousand hepatologist and infectious diseases specialist on the most recent treatments for hepatitis patients, as well as ultrasound diagnostic measures.


Download as PDF

EVA Pharma Explores the Manufacturing of COVID-19 Vaccines with European and American Companies


Cairo, July 28, 2020 – EVA Pharma announced its efforts at concluding cooperation agreements to manufacture a vaccine for the novel coronavirus in Egypt.

In the meantime, Dr. Riad Armanious, EVA Pharma’s CEO, said that they started communicating with various international companies, both European and American, working on the development of coronavirus vaccine and that EVA Pharma is willing and prepared to cooperate with all parties that will provide the Egyptian patient with a head start at attaining the COVID-19 vaccine.

In his press statement, earlier today, Armanious added that the manufacturing of the vaccine in Egypt will ensure its affordability to the Egyptian patient & the availability in any quantities needed by the national market in addition to its high quality.

Armanious emphasized the company’s keenness to cover the needs of the Egyptian patient while facing the coronavirus, including antiviral treatments, immunity-boosting agents, all supportive treatments in addition to the vaccine.

He clarified that his company started implementing a massive national project to build the first medical city specialized in manufacturing human and veterinary vaccines in Egypt, Africa and the middle east.

This step comes in alignment with the company’s mission to secure the needs of the Egyptian citizens as well as citizens in all the continents where the company operates. The first phase of the project will include veterinary vaccines along with the quest to produce COVID-19 vaccines after proven effective globally.

The company consulted two of the biggest international expert houses to develop construction designs of the human and veterinary vaccine plant according to the global standards, before the emerging of the novel coronavirus. The plant will contribute towards the self-sufficiency of the vaccines and provide Egypt with hard currency with the export.

Armanious added, “owning a medical city that is specialized in producing vaccines will enable Egypt to produce, with high speed and quality, vaccines against any future microbial threat; as it will also open doors to collaboration with the leading global institutes in the vaccination field including vaccines against different viruses”.

Armanious pointed that EVA Pharma’s first vaccine product will be released before the end of 2020, as it will be used to vaccinate a huge amount of birds and poultry against winter-related viruses as “influenza” and “Newcastle disease”. The project, as highlighted by Armanious, will protect almost 10% of Egypt’s poultry fortune from winter-related respiratory viruses, a number that is estimated from 100 to 200 million different birds.

The vaccine city will be complete within 3 to 5 years, the time which EVA Pharma is investing in preparing the manufacturing process of different vaccines.

From his part, Dr. Ayman Al-Deib, assistant professor in viruses at the veterinary medical college in Cairo University and the technical consultant of EVA Pharma on its veterinary vaccinations portfolio, said the company has already successfully registered two veterinary vaccines which will be its first vaccine products.

Al-Deib added, the two vaccines will be available at the national markets within 2 to 3 months at the most estimate, with the help and cooperation of the Serums and Vaccines Research Institute of Ministry of Agriculture and Land Reclamation.

Clarifying that such vaccines are usually imported, Al-Deib said that the Egyptian vaccines will reduce the influenza and Newcastle disease death toll of poultry, which resolves a big problem at the poultry industry, when a safe, high quality and affordable vaccine is available.

download as pdf

The Telegraph announced that “Sofosbuvir” and “Daclatasvir” Produced by EVA Pharma are reducing Coronavirus Death Rate

Cairo, July 11, 2020 A number of countries are currently investigating the effects of two hepatitis C treatments on reducing the death rate of coronavirus. Three trials involved patients in Iran, along with other similar trials simultaneously conducted in other countries.

The trials included “Sofosbuvir” and “Daclatasvir”; both drugs are produced by EVA Pharma, one of the major international pharmaceutical companies headquartering in Cairo while operating in more than 40 countries. The two drugs were used during the country’s campaign to eliminate hepatitis C from Egypt.

According to The Telegraph, “Three groups of patients were given the two drugs, with affordable cost of the treatment compared to other tested COVID-19 treatments” the results of such trials were described as “promising”.

The mechanism of action for the mentioned treatments, by binding to one of the proteins of the virus, interfering with its ability to replicate. The results of the trials are expected to be concluded and revealed in October.

In his comment on the current studies, Dr. Riad Armanious, CEO of EVA Pharma, assured the company’s commitment to producing both drugs at enough quantities to cover the Egyptian needs especially with EVA Pharma having vast manufacturing capabilities that allow export.

Armanious also highlighted that now EVA Pharma offers Egypt and all countries in the region, all the treatment options available to combat coronavirus. Starting from the antivirals “Remdesivir – EVA Pharma”, up to “Sofosbuvir” and “Daclatasvir” and all other drugs included in COVID-19 treatment will be made available in high-value and affordable cost to the Egyptian patient.

While pointing that his company produces a group of vitamins and immunity boosters as vitamin C and zinc, vitamin B complex, along with other needed drugs that allow Egypt’s “White Army” to treat COVID-19 patients in Egyptian hospitals, and other countries in the region and globally.

Armanious revealed that EVA Pharma has already released Remdesivir to nearly 30 hospitals around Egypt, while now is getting ready to export abroad in the upcoming few days.

Wrapping his statement, Armanious assured again in his company’s quest to provide all and any treatment production amounts serving the best interest of the Egyptian patient, and openness to abroad export.


Download as PDF

EVA Pharma launches the first Egyptian medication for Chronic Obstructive Pulmonary Disease


Cairo, July 20, 2020 – EVA Pharma today announced the launch of the Egyptian drug Inhalex® (tiotropium) a long-acting bronchodilator for the treatment of chronic obstructive pulmonary disease (COPD) which will reduce the cost of treatment for the patient to half.

“Throughout 5 years of work and consulting German expertise, we have been able to manufacture this high-quality product,” said one of the researchers at EVA Pharma on Inhalex.

“Inhalex reduces the cost of treatment to half.” said Dr.Ashraf Hatem, member of the High Committee for Respiratory Viruses at the Ministry of Higher Education & Scientific Research, the former Minister of Health and Population “As smokers, secondhand smokers and who are exposed to severe pollution are the most affected, this treatment helps COPD patients breathe normally throughout the day.”

In his press statement earlier today, Dr.Hatem said that the disease prevalence is 5-10% of the population, estimating that 10 million Egyptians suffer from COPD & it’s prevalent not only in Egypt but also globally.

The Egyptian drug “Inhalex”, a generic product for a similar previously imported drug, will reduce the patient’s treatment cost to half, as it’s a medicine that has to be administered daily for a lifetime.

Hatem added, “COPD patients had no other option but to buy the imported drug, to help them breathe normally to be able to do their daily activities. The Egyptian “Inhalex” will provide an affordable treatment, regular availability in the Egyptian market and a 24-hour lasting effect of the treatment”

“COPD patient needs this treatment for life; it is important for the patient to have a generic drug similar to the imported treatment in the Egyptian market with an affordable price since the imported drug is double the cost of the Egyptian Inhalex” stated Hatem.

He also emphasized the importance of asthma and COPD patients’ adherence to their daily treatment to avoid exacerbation of viral infections including the COVID-19 and to have fewer effects in case the patients have a viral exacerbation.

Hatem valued the efforts made by EVA Pharma to produce this drug in Egypt, including importing the pharmaceutical active ingredients and the apparatus used to inhale the active ingredient, along with high manufacturing quality. Illustrating that “a good generic product attracts the patient due to its effectiveness and affordability.”


EVA Pharma, one of the major multinational pharmaceutical companies headquartering in Cairo while operating in more than 40 countries, is currently launching “Inhalex” in the national market. The new drug “Inhalex” has the same quality as the imported drug with a 50% price reduction. And EVA Pharma is able to provide any required quantity to the national market, along with international export” said Dr. Mina Henien, a senior R&D manager at EVA Pharma’s Mounir Armanious Research Center (MARC).


He added that EVA Pharma owns a set of laboratories that ensures the product’s quality, as Inhalex was tested on an artificial lung to ensure the product’s high effectiveness as part of the testing process applied at the top international companies of the pharmaceutical field. Henien explained that EVA Pharma has been examining the manufacturing of this drug 5 years ago, while delegates from the company traveled to Kiel University in Germany to share their experience in this field for the highest international manufacturing quality. The new drug delivers the active constituent directly to the lung via an inhaler that is included in each package of Inhalex, thus ensuring optimal treatment effectiveness for the patient.


About Inhalex®

Its active ingredient is (tiotropium), a long-acting bronchodilator used in the management of chronic obstructive pulmonary disease and asthma. Which provides affordable treatment, regular availability in the Egyptian market, and a 24-hour lasting effect.

About COPD

The major cause of COPD prevalence in Egypt and the world is cigarette or hookah smoking. Its symptoms include cough, shortness of breath, and inability to breathe normally.

COPD is more common in men, due to smoking, but there is prevalence among women in Upper Egypt who use traditional ovens and have been exposed to smoke for long periods, or who are living in areas with severely polluted air for a long time.


About EVA Pharma

EVA Pharma, one of the major multinational pharmaceutical companies headquartering in Cairo, Egypt while operating in more than 40 countries and one of the fastest-growing pharmaceutical companies in the MENA region. The company has partnerships with some of the leading international pharmaceutical names the world over and has a presence in 41 countries throughout the region. With a 3,000-strong team of some of the region’s most competent pharmaceutical professionals, Eva Pharma produces an average of 350,000 packs of more than 165 different drugs daily. Its state-of-the-art facilities are equipped with cutting-edge technology and are internationally recognized for innovation and the highest international quality standards.

Download as PDF